Chemistry:RG-7410

From HandWiki

RG-7410 is a trace amine-associated receptor 1 (TAAR1) agonist which was under development for the treatment of schizophrenia but was never marketed.[1][2] Its route of administration was unspecified.[1]

The drug reached phase 1 clinical trials prior to the discontinuation of its development.[1][2] It was under development by Hoffmann-La Roche.[1][2] RG-7410 was first disclosed by January 2014[3] and a phase 1 trial was reported to have been completed by October 2014.[4]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 "RG 7410". 13 October 2015. https://adisinsight.springer.com/drugs/800038118. 
  2. ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on RG-7410 with Synapse". 19 September 2024. https://synapse.patsnap.com/drug/03b4401803fc479985e533069a1366be. 
  3. ↑ "Roche 2013 results". Roche Group. London. 30 January 2014. https://assets.roche.com/f/176343/b9882c9bf5/irp140130.pdf. 
  4. ↑ "Pipeline summary". Roche Group. https://jamesjungkuelee.wordpress.com/wp-content/uploads/2015/01/jpm-2015-roche.pdf. "Changes to the development pipeline Q3 2014 update" 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:RG-7410&oldid=4032506"